Galmed Pharmaceuticals has announced significant results from a pharmacokinetics study of Aramchol Meglumine, showing a remarkable 500% increase in bioavailability compared to standard formulations.

Galmed Pharmaceuticals, in collaboration with Barcode Nanotech, has announced the development of a new formulation for its SCD1 inhibitor, Aramchol, which can now successfully cross the blood-brain ba

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Ar

   Rebeca Torró insta a la Generalitat a sumarse para "aunar fuerzas y aprovechar todas las...

Hace más de un año se anunció el cierre de la compañía industrial y tras meses de incertidumbre, se prevé el traspaso de las acciones a Network Steel para finales de dici

Alt: a woman in a white robe is laying on a bed with pillows and a bag that says prada on it

Galmed Pharmaceuticals has rebranded itself as EoCene and has introduced a new Nasdaq ticker symbol, EOCN. This change aims to highlight its innovative focus on gastrointestinal health.

Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company. It focuses on developing treatments for liver diseases and related metabolic conditions. On August 19, 2026, the…

Galmed Pharmaceuticals recently completed a successful clinical study for their Colospan technology, enhancing intraoperative assessment of colon tissue quality, promising better surgical outcomes.

Galmed Pharmaceuticals (NASDAQ: GLMD) announced that its wholly owned subsidiary Colospan completed a first-in-human, prospective single-arm feasibility study of a novel intraoperative colon tissue quality assessment platform in 32 colorectal cancer patients undergoing elective surgery at three leading medical centers in Israel.The study demonstrated that quantitative measurement of colon tissue compliance using a novel ex-vivo methodology was technically feasible, with successful measurements in all 32 patients and no measurement failures or procedure-related technical issues. These results establish a clinical foundation for continued development of an intraoperative device to provide surgeons with objective, real-time tissue quality data, complementing Colospan’s CG-100 intraluminal bypass device and supporting Galmed’s strategy to build a diversified GI oncology and colorectal surgery portfolio.

The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality. The study establishes the clinical foundation for...

Reported Tuesday, Aug 18 - 7:50pm EDT (TheFly subscription required to read more.)

Galmed Pharmaceuticals has unveiled promising results from its studies on Aramchol, revealing significant enhancements in prostate cancer treatment when combined with Xtandi®.

Reported Monday, Aug 17 - 9:18am EDT (TheFly subscription required to read more.)

Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global...

Galmed Pharmaceuticals reveals their innovative dispersible film delivery system for Aramchol, targeting Parkinson's disease and enhancing treatment efficacy.